HUP0202938A3 - N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them - Google Patents

N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them

Info

Publication number
HUP0202938A3
HUP0202938A3 HU0202938A HUP0202938A HUP0202938A3 HU P0202938 A3 HUP0202938 A3 HU P0202938A3 HU 0202938 A HU0202938 A HU 0202938A HU P0202938 A HUP0202938 A HU P0202938A HU P0202938 A3 HUP0202938 A3 HU P0202938A3
Authority
HU
Hungary
Prior art keywords
sulfonamidobenzamides
aryl
pharmaceutical compositions
compositions containing
transport inhibitors
Prior art date
Application number
HU0202938A
Other languages
Hungarian (hu)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of HUP0202938A2 publication Critical patent/HUP0202938A2/en
Publication of HUP0202938A3 publication Critical patent/HUP0202938A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0202938A 1999-07-20 2000-07-19 N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them HUP0202938A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14464699P 1999-07-20 1999-07-20
PCT/US2000/019616 WO2001005398A1 (en) 1999-07-20 2000-07-19 Phosphate transport inhibitors

Publications (2)

Publication Number Publication Date
HUP0202938A2 HUP0202938A2 (en) 2003-01-28
HUP0202938A3 true HUP0202938A3 (en) 2006-07-28

Family

ID=22509500

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202938A HUP0202938A3 (en) 1999-07-20 2000-07-19 N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them

Country Status (19)

Country Link
EP (1) EP1202729A1 (en)
JP (1) JP2003504403A (en)
KR (1) KR20020015382A (en)
CN (1) CN1361687A (en)
AR (1) AR030911A1 (en)
AU (1) AU6354300A (en)
BR (1) BR0012568A (en)
CA (1) CA2379657A1 (en)
CO (1) CO5190714A1 (en)
CZ (1) CZ2002204A3 (en)
HU (1) HUP0202938A3 (en)
IL (1) IL147697A0 (en)
MX (1) MXPA02000753A (en)
NO (1) NO20020278L (en)
NZ (1) NZ516619A (en)
PL (1) PL353741A1 (en)
TR (1) TR200200112T2 (en)
WO (1) WO2001005398A1 (en)
ZA (1) ZA200200464B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL359931A1 (en) * 2000-05-12 2004-09-06 Smithkline Beecham Corporation Phosphate transport inhibitors
GB2378179A (en) * 2001-08-03 2003-02-05 Pantherix Ltd Aromatic sulfonamides and their use in treating bacterial diseases
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7582673B2 (en) 2004-10-21 2009-09-01 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
WO2006077901A1 (en) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf expression inhibitor
JP2011523655A (en) * 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー Pharmaceutical composition comprising a gamma secretase modulator
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (en) 2008-12-31 2017-01-04 阿德利克斯公司 For treating the disease relevant with fluid retention or salt over loading and the Compounds and methods for of disorder of gastrointestinal tract
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827326B2 (en) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103183623A (en) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof
EP2983667B1 (en) 2013-04-12 2019-03-20 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
CN105395532B (en) * 2015-11-25 2017-11-14 中国医学科学院医药生物技术研究所 Application of the 2 benzene sulfonamido benzamide compounds in liver injury protection and liver fibrosis preventing and treating
JP6713051B2 (en) * 2016-08-30 2020-06-24 日本曹達株式会社 Sulfonylaminobenzamide compounds and pest control agents
CN118221656A (en) 2017-01-09 2024-06-21 阿德利克斯股份有限公司 Compounds useful for the treatment of gastrointestinal disorders
BR112019013963A2 (en) 2017-01-09 2020-04-28 Ardelyx Inc nhe-mediated antiport inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Also Published As

Publication number Publication date
HUP0202938A2 (en) 2003-01-28
CA2379657A1 (en) 2001-01-25
NZ516619A (en) 2004-02-27
IL147697A0 (en) 2002-08-14
BR0012568A (en) 2002-04-30
MXPA02000753A (en) 2002-07-22
ZA200200464B (en) 2003-04-30
KR20020015382A (en) 2002-02-27
AU6354300A (en) 2001-02-05
CO5190714A1 (en) 2002-08-29
NO20020278D0 (en) 2002-01-18
NO20020278L (en) 2002-01-18
TR200200112T2 (en) 2002-05-21
PL353741A1 (en) 2003-12-01
EP1202729A1 (en) 2002-05-08
JP2003504403A (en) 2003-02-04
CN1361687A (en) 2002-07-31
WO2001005398A1 (en) 2001-01-25
CZ2002204A3 (en) 2002-11-13
AR030911A1 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
HUP0202938A3 (en) N-aryl-2-sulfonamidobenzamides as phosphate transport inhibitors and pharmaceutical compositions containing them
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
HUP0300318A3 (en) Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use
HUP0202897A3 (en) Diaminothiazoles and their use for inhibiting protein kinases and pharmaceutical compositions containing them
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
HUP0200347A3 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
IL140338A0 (en) Amino acid derivatives which inhibit dipeptidyl peptidase iv and pharmaceutical compositions containing the same
HUP0200355A3 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0500173A3 (en) Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
HUP0105113A3 (en) Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
HUP0000167A3 (en) Pyrroles as spla2 inhibitors, and pharmaceutical compositions containing them
IL148489A0 (en) Quinazoline compounds and pharmaceutical compositions containing them
HK1048589A1 (en) Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
HUP0100186A3 (en) Compounds as lactam metalloprotease inhibitors and pharmaceutical compositions containing them
HUP0203575A3 (en) Pharmaceutical compositions containing th2 differentiation inhibitors and their use
IL164022A0 (en) Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
HUP0202891A3 (en) Biphenyl derivatives used as nhe-3 inhibitors and pharmaceutical compositions containing them
HUP0002951A3 (en) Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
HUP0001632A3 (en) Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same
HUP0104657A3 (en) Imidazole compounds and pharmaceutical compositions containing them
HUP0201846A3 (en) Amonobenzophenones as inhibitors of il-1betha and tnf-alpha and pharmaceutical compositions containing them
HUP0103382A2 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished